title: Acute and Chronic Effects of N-acetylcysteine on Pentylenetetrazole-induced Seizure and Neuromuscular Coordination in Mice.
abstract: BACKGROUND
  N-acetylcysteine (NAC) has been indicated against experimental seizures, but with relatively inconclusive results. This study was undertaken to evaluate whether NAC exerts a dose-dependent anticonvulsant effect and to determine NAC safe therapeutic dose range and its muscle-relaxant activity in both acute and chronic uses.
  
  
  METHODS
  Following intraperitoneal (i.p.) administration of N-acetylcysteine acutely (50-300 mg/kg) or chronically for 8 days (25-300 mg/kg), mice were injected with PTZ (90 mg/kg, i.p.) and latency times to the onset of myoclonic and clonic seizures and protection against death were recorded. Changes in body weight and mortality rate were considered as parameters for drug safety. The muscle-relaxant activity of NAC was assessed by rotarod test.
  
  
  RESULTS
  Acute and chronic treatment with NAC delayed latency times to myoclonic and clonic seizures in a dose-dependent manner, but with no significant prevention against PTZ-induced death. Chronic administration of 300 mg/kg NAC was fully lethal while lower doses (100 and 150 mg/kg) resulted in a significant weight loss and decreased stay time on rotarod. Acute treatment with NAC had no significant effect on stay time on rotarod at all studied doses.
  
  
  CONCLUSIONS
  NAC exerts a dose-dependent anticonvulsant effect in acute and chronic uses, with no muscle relaxant activity. NAC has higher efficacy in preventing seizure in chronic than acute treatment, but its chronic use at higher doses of 75 mg/kg may be associated with side effects and/or toxicity. These findings suggest that low doses of NAC may have a potential use as a prophylactic treatment for absence seizure in human.
authors.affiliation: Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Sasan
authors.initials: S
authors.lastname: Zaeri
authors.affiliation: Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ; Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Masoumeh
authors.initials: M
authors.lastname: Emamghoreishi
keywords: Anticonvulsant; N-acetylcysteine; Pentylenetetrazole; Seizure
references.citation: Drugs Aging. 2001;18(2):133-42
references.pmid: 11346127
references.citation: Nitric Oxide. 2005 Aug;13(1):10-20
references.pmid: 15914045
references.citation: Intensive Care Med. 2000 Feb;26(2):215-7
references.pmid: 10784312
references.citation: Pharmacol Biochem Behav. 2005 Sep;82(1):241-5
references.pmid: 16185759
references.citation: FASEB J. 2008 Mar;22(3):659-61
references.pmid: 17942826
references.citation: Seizure. 2013 Sep;22(7):577-80
references.pmid: 23664806
references.citation: CNS Neurosci Ther. 2012 May;18(5):406-13
references.pmid: 22537319
references.citation: Epilepsy Res. 2004 Nov;62(1):65-74
references.pmid: 15519133
references.citation: Neurosci Lett. 2007 Jun 8;420(1):76-9
references.pmid: 17512118
references.citation: J Neurol Sci. 2011 Sep 15;308(1-2):35-40
references.pmid: 21737104
references.citation: Epilepsia. 1989;30 Suppl 1:S51-6; discussion S64-8
references.pmid: 2776711
references.citation: Basic Clin Pharmacol Toxicol. 2006 May;98(5):521-2
references.pmid: 16635113
references.citation: Pharmacol Biochem Behav. 2003 Feb;74(3):579-85
references.pmid: 12543222
references.citation: Epilepsy Res. 2000 Jun;40(1):33-9
references.pmid: 10771256
references.citation: Fundam Clin Pharmacol. 2006 Jun;20(3):247-53
references.pmid: 16671959
references.citation: Eur Respir J. 2004 Apr;23(4):629-36
references.pmid: 15083766
references.citation: J Appl Physiol (1985). 2005 Dec;99(6):2271-7
references.pmid: 16099896
references.citation: Neuroscience. 2012 Sep 18;220:85-9
references.pmid: 22732503
references.citation: Biochem Soc Trans. 2007 Nov;35(Pt 5):1228-31
references.pmid: 17956319
references.citation: Neurochem Res. 2005 Sep;30(9):1117-21
references.pmid: 16292504
references.citation: Comp Biochem Physiol C Toxicol Pharmacol. 2002 Apr;131(4):521-9
references.pmid: 11976067
references.citation: Trends Pharmacol Sci. 2008 Jul;29(7):346-51
references.pmid: 18538422
references.citation: J Neurochem. 2004 Feb;88(3):657-67
references.pmid: 14720215
references.citation: Neurosci Lett. 2007 Jan 10;411(2):152-7
references.pmid: 17092649
references.citation: J Nutr. 2000 May;130(5S Suppl):1493S-9S
references.pmid: 10801965
references.citation: Pharmacol Biochem Behav. 2003 Jan;74(2):303-11
references.pmid: 12479949
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 May;27(3):487-92
references.pmid: 12691785
references.citation: Neurosci Lett. 2004 Mar 4;357(2):83-6
references.pmid: 15036580
references.citation: Expert Opin Pharmacother. 2008 Dec;9(18):3169-77
references.pmid: 19040338